Knockdown of STC2 compromises the colony formation; while ectopic expression of STC2 promotes cell proliferation [36], indicating STC2 may serve as a novel diagnostic biomarker for aggressive prostate cancer and a new therapeutic target for CRPC. Here, STC2 is linked to Familial prostate cancer.